This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2022
  • /
  • 11
  • /
  • Toripalimab filed with EU for nasopharyngeal carci...

Toripalimab filed with EU for nasopharyngeal carcinoma

Read time: 1 mins
Published:16th Nov 2022

Shanghai Junshi Biosciences has submitted a marketing authorization application to the European Medicines Agency for toripalimab

The indication requested in the MAA is for toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma.

The MAA submission for NPC is based on the results from JUPITER-02 (an international randomized, placebo-controlled, double-blinded Phase III trial, NCT03581786) and POLARIS-02 (a multi-center, open label, pivotal Phase II clinical trial, NCT02915432). The JUPITER-02 results were first presented in June 2021 in a plenary session of the American Society of Clinical Oncology annual meeting (#LBA2) and subsequently published in detail as the cover article of the September 2021 issue of Nature Medicine. The POLARIS-02 results were published online in January 2021 in the Journal of Clinical Oncology.

Condition: Nasopharyngeal Carcinoma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.